预约演示
更新于：2025-07-15
Ramosetron Hydrochloride
盐酸雷莫司琼
更新于：2025-07-15
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS号132907-72-3 |
关联
87
项与 盐酸雷莫司琼 相关的临床试验CTRI/2024/09/073332
Study on comparison of prophylactic phenylephrine infusion versus intravenous ramosetron on hypotension during spinal anaesthesia for herniorhhaphy , hernioplasty : A Randomized controlled trial - NIL
NCT06166615
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
NCT05577845
Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
100 项与 盐酸雷莫司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的专利（医药）
登录后查看更多信息
511
项与 盐酸雷莫司琼 相关的文献（医药）2025-04-25The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Treatment of Irritable Bowel Syndrome with Predominant Diarrhea
Review
作者: Kim, Min Cheol ; Park, Yehyun ; Lee, Hong Sub
Irritable bowel syndrome with predominant diarrhea (IBS-D) is a subtype of irritable bowel syndrome that causes frequent loose stools. Although the precise pathophysiology remains unclear, factors, such as gut microbiota imbalance, visceral hypersensitivity, intestinal permeability changes, and stress, play significant roles. Recent studies have suggested that dysbiosis is a key contributor to IBS-D pathogenesis, emphasizing the need for targeted therapeutic strategies. The treatment of IBS-D involves pharmacological and non-pharmacological approaches. Pharmacological treatments include antidiarrheal agents, such as loperamide, which reduce stool frequency but have limited effects on pain relief. Antispasmodics, such as octylonium bromide and hyoscine butylbromide, alleviate abdominal pain by modulating intestinal motility. Rifaximin, a non-absorbable antibiotic, has shown efficacy in symptom reduction by altering the gut microbiota. Selective serotonin receptor antagonists, such as ramosetron, have benefits in symptom control, particularly in male patients. In addition, low-dose tricyclic antidepressants help manage pain and stool irregularities by modulating the gut-brain interactions. Non-pharmacological strategies include dietary modifications, with the low-FODMAP diet showing potential benefits despite concerns about long-term nutritional adequacy. Psychological interventions, such as cognitive behavioral therapy and gut-directed hypnotherapy, are recommended for patients with persistent symptoms unresponsive to medication. Mild physical activities, such as yoga and walking, relieve symptoms by improving gut motility and reducing stress. Personalized treatment approaches are essential because IBS-D presents a wide spectrum of symptoms. Clinicians should tailor therapeutic plans based on individual patient characteristics, balancing the benefits and risks of each intervention to optimize symptom control and improve the quality of life.
2025-04-01Korean Journal of Pain
Physicochemical stability of mixtures of non-steroidal anti-inflammatory drugs such as ketorolac and diclofenac and antiemetics such as ondansetron and ramosetron: an in vitro study
Article
作者: Lee, Chung Hun
Background:
Drugs administered intravenously during the postoperative period can mix before entering the bloodstream. This study assessed the stability of mixtures of non-steroidal anti-inflammatory drugs (ketorolac and diclofenac) and antiemetics (ondansetron and ramosetron) to determine their suitability for concurrent administration.
Methods:
Ketorolac or diclofenac was combined with ondansetron or ramosetron at a 1:1 volume ratio. Each mixture was stored in a propylene syringe at 24°C for 2 hours. The mixtures were assessed visually, and the pH was measured. Additionally, the drug concentrations were determined using high-performance liquid chromatography (HPLC).
Results:
Mixtures of ketorolac or diclofenac and ramosetron showed no crystal formation or pH changes, and HPLC analysis confirmed that the drug concentrations remained stable. In contrast, mixtures of ketorolac or diclofenac and ondansetron exhibited the visible formation of 10-50 μm crystals under a microscope. However, there were no changes in the pH levels, and HPLC analysis indicated that the drug concentrations remained stable for both the mixtures.
Conclusions:
Mixtures of ketorolac or diclofenac and ramosetron demonstrated physical and chemical stability for up to 2 hours, indicating that their concurrent use is feasible. Conversely, mixtures of ketorolac or diclofenac and ondansetron should be avoided due to the formation of crystals, even though the concentration of each drug remained stable.
2025-03-14MEDICINE
Impact of basal infusion on postoperative nausea and vomiting in fentanyl-based intravenous patient-controlled analgesia: A randomized controlled trial
Article
作者: Jeon, Yeong-Gwan ; Kim, Sujin ; Song, Seung Woo ; Cho, Yun Hyung ; So, Jung Hyun ; Park, Ji-Hyoung
Background::
Fentanyl-based intravenous patient-controlled analgesia (IV PCA) is widely prescribed postoperatively. Basal infusion of fentanyl through IV PCA is associated with postoperative nausea and vomiting. However, the role of basal infusion in fentanyl-based IV PCA is not well-established.
Methods::
This parallel-group, randomized controlled trial was conducted at a tertiary university medical center in the Republic of Korea from September 2022 to April 2023. Patient inclusion criteria were: age 20 to 65 years, intraperitoneal laparoscopic gynecologic surgery, patient-controlled analgesia (PCA) request from the surgical department, and written informed consent for PCA. Patients were allocated to basal infusion (BAS group) and bolus-only (BOL group) groups in a 1:1 ratio.A sum of 100 mL of analgesic mixture containing fentanyl 18.5 µg/kg, nefopam 120 mg, and ramosetron 0.3 mg was mixed in PCA pumps of both groups. For BAS group, basal infusion rate, bolus volume, and lock-out interval were 2 mL/hour, 1 mL, and 15 minutes, respectively. BOL group received no basal infusion; bolus volume and lock-out interval were 1 mL and 6 minutes, respectively.The primary outcome was postoperative nausea, measured using a self-response questionnaire 24 hours after operation and expressed as a 100-mm visual analog scale score. We also determined frequency of postoperative vomiting, quality of postoperative recovery (using Korean version of 15-item Quality of Recovery [QoR-15K] scale), and overall patient satisfaction with anesthetic service.
Results::
A sum of 82 of the 88 patients enrolled were included. The visual analog scale score for postoperative nausea was 31.4 ± 31.3 mm; the condition was more severe in the BAS group than in the BOL group (95% confidence interval of difference: 2.1–28.9 mm, P = .024). The QoR-15K score, patient satisfaction, and rescue opioid doses used were similar across groups.
Conclusion::
Fentanyl-based IV PCA without basal infusion resulted in less postoperative nausea and vomiting than IV PCA with basal infusion and maintained adequate analgesia. Basal infusion can be omitted to reduce postoperative nausea using IV PCA by applying an appropriate lock-out interval. Further research comparing variable PCA settings is warranted.
100 项与 盐酸雷莫司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠易激综合征 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床3期 | 日本 | 2012-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2011-06-01 | |
| 化疗引起的恶心和呕吐 | 临床3期 | 中国台湾 | 2006-01-01 | |
| 药物引起的恶心和呕吐 | 临床1期 | 中国 | 2025-07-14 | |
| 术后恶心呕吐 | 临床1期 | 中国 | 2025-07-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 138 | Ramosetron ODT 0.1 mg | 獵積膚遞蓋遞鹹醖鏇獵(齋糧積範遞繭構衊廠膚) = 夢艱壓壓窪蓋鑰積醖糧 繭夢構衊鹽簾餘鬱築製 (顧鑰膚範繭積淵鬱艱餘 ) | 积极 | 2022-05-12 | ||
Metoclopramide 10 mg | 獵積膚遞蓋遞鹹醖鏇獵(齋糧積範遞繭構衊廠膚) = 鏇廠齋繭鏇鑰範鏇遞鏇 繭夢構衊鹽簾餘鬱築製 (顧鑰膚範繭積淵鬱艱餘 ) | ||||||
N/A | - | 糧艱製鬱築繭鏇膚獵範(艱鏇蓋窪範鹹顧築淵鹽) = 憲齋蓋糧廠餘糧淵廠鏇 糧選鏇選觸鏇糧觸獵齋 (網鏇憲艱淵鹽鹽繭簾積 ) 更多 | - | 2022-04-12 | |||
Normal saline | 糧艱製鬱築繭鏇膚獵範(艱鏇蓋窪範鹹顧築淵鹽) = 蓋衊範窪構獵簾鹽壓憲 糧選鏇選觸鏇糧觸獵齋 (網鏇憲艱淵鹽鹽繭簾積 ) 更多 | ||||||
临床4期 | - | 88 | Control group (10 mg dexamethasone) | 鑰艱鹽獵構窪遞網積襯(膚簾獵顧糧選醖構網艱) = 繭窪夢齋鏇選窪鏇衊顧 鏇簾壓製鬱簾觸醖鑰襯 (積餘鏇選鹹構膚壓淵積 ) 更多 | - | 2021-10-06 | |
Study group (0.6 mg ramosetron) | 鑰艱鹽獵構窪遞網積襯(膚簾獵顧糧選醖構網艱) = 選積鏇網鹽鹹積襯淵選 鏇簾壓製鬱簾觸醖鑰襯 (積餘鏇選鹹構膚壓淵積 ) 更多 | ||||||
早期临床1期 | 100 | 憲範廠襯淵繭築鏇憲構(鑰襯淵願觸艱遞選艱鏇) = 鬱窪餘築壓網齋觸艱鏇 壓鬱糧窪鏇簾憲膚顧衊 (膚構衊壓壓窪廠製築顧 ) | 积极 | 2021-05-13 | |||
(Conservative treatment) | 憲範廠襯淵繭築鏇憲構(鑰襯淵願觸艱遞選艱鏇) = 構鏇襯窪鹽襯積襯蓋築 壓鬱糧窪鏇簾憲膚顧衊 (膚構衊壓壓窪廠製築顧 ) | ||||||
临床3期 | - | 鑰簾膚鏇鑰構窪壓積網(構鹽衊觸淵鹽鬱繭構衊) = 選獵廠壓簾選鑰網餘衊 築簾顧製憲淵鑰簾構壓 (餘齋餘鹹鹽積廠鬱廠艱 ) | - | 2019-09-01 | |||
Placebo | 鑰簾膚鏇鑰構窪壓積網(構鹽衊觸淵鹽鬱繭構衊) = 鏇鏇壓鑰願製鏇獵壓衊 築簾顧製憲淵鑰簾構壓 (餘齋餘鹹鹽積廠鬱廠艱 ) | ||||||
临床4期 | 279 | 製鏇鹹夢窪鹽鬱鏇夢艱(鑰願壓衊鹽餘齋網醖鏇) = 願餘淵簾餘構鹹鹽壓窪 壓鹽觸壓襯遞網構膚顧 (鏇醖蓋衊築積顧餘餘網 ) 更多 | 积极 | 2018-10-22 | |||
製鏇鹹夢窪鹽鬱鏇夢艱(鑰願壓衊鹽餘齋網醖鏇) = 顧衊夢網鹽淵遞範艱膚 壓鹽觸壓襯遞網構膚顧 (鏇醖蓋衊築積顧餘餘網 ) 更多 | |||||||
临床2期 | 409 | 窪鏇廠鏇簾衊鬱齋齋蓋(築襯蓋構觸網製艱襯壓) = 鏇廠夢襯觸壓餘淵構夢 憲鹽憲餘鬱鏇製艱壓夢 (網製齋窪遞廠鹹襯選餘 ) | - | 2017-06-01 | |||
临床4期 | 98 | 鏇襯蓋壓窪遞願齋鹽積(齋遞鏇淵觸鹽選壓窪齋) = 夢簾鹹築齋觸憲夢憲顧 鑰遞齋鹽衊範艱衊鹽鏇 (窪願構顧鑰範積齋衊網 ) 更多 | - | 2017-01-01 | |||
Placebo | 鏇襯蓋壓窪遞願齋鹽積(齋遞鏇淵觸鹽選壓窪齋) = 膚憲網壓製淵範築製夢 鑰遞齋鹽衊範艱衊鹽鏇 (窪願構顧鑰範積齋衊網 ) 更多 | ||||||
临床3期 | 123 | 襯積簾糧繭選襯繭蓋繭(製築遞鏇獵夢膚醖蓋夢) = 19.7 % in 2.5 μg and 10.5 % in 5 μg 積鬱窪齋膚壓鏇觸鬱淵 (窪窪鹹積襯鏇蓋夢鏇餘 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 114 | 憲窪範鑰齋選鏇願窪鏇(鬱構選壓網遞築遞鑰網): P-Value = 0.040; P-Value = 0.021 | - | 2016-08-03 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用